Browsing: weightloss

Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge following the news of these discussions. The company focuses on mental health treatments using psychedelic-based compounds. AtaiBeckley is developing an intranasal formulation for treatment-resistant depression. Talks are ongoing, and a deal could be announced this week

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for body weight reduction, there remains a critical unmet need for complementary strategies that drive selective fat loss and sustain long-term weight reduction. This study aimed to investigate whether Vutiglabridin, a novel oral small-molecule anti-obesity drug, complements GLP-1 RAs to enhance therapeutic efficacy by selectively…